Publications by authors named "Guido Parvis"

Claim this Profile
I
Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach.
Antonio Frolli, Guido Parvis, Martina Bullo, Selene Grano, Giovanni Fornari

Hematol Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Andrea Gallamini, Corrado Tarella, Simonetta Viviani, Andrea Rossi, Caterina Patti, Guido Parvis

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Radiation-Free Approach Based on the Whole-Body MRI Has Shown a High Level of Accuracy in the Follow-Up of Lymphoma Patients-A Single Center Retrospective Study.
Antonio Frolli, Sivlia Varvello, Annalisa Balbo Mussetto, Daniela Gottardi, Martina Bullo, Guido Eugenio Parvis

J Clin Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose radiotherapy for extranodal marginal zone B lymphoma of the lip: Case report and literature review.
Lavinia Bianco, Salvatore Dario Solla, Guido Parvis, Eva Gino, Enrico Bollito

Hematol Oncol Stem Cell Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.
Alessandra Romano, Chiara Pavoni, Francesco Di Raimondo, Corrado Tarella, Simonetta Viviani, Guido Parvis

Cancer Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.
Giovanna Carrà, Paolo Nicoli, Marcello Francesco Lingua, Beatrice Maffeo, Antonio Cartellà, Guido Parvis

J Cell Mol Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
Riccardo Bruna, Fabio Benedetti, Carola Boccomini, Caterina Patti, Anna Maria Barbui, Guido Parvis

Haematologica· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Andrea Gallamini, Corrado Tarella, Simonetta Viviani, Andrea Rossi, Caterina Patti, Guido Parvis

J Clin Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Giovanna Carrà, Cristina Panuzzo, Davide Torti, Guido Parvis, Sabrina Crivellaro

Oncotarget· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
Mario Levis, Cristina Piva, Andrea Riccardo Filippi, Barbara Botto, Paolo Gavarotti, Guido Parvis

Clin Lymphoma Myeloma Leuk· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffusion-weighted quantitative MRI to diagnose benign conditions from malignancies of the anterior mediastinum: Improvement of diagnostic accuracy by comparing perfusion-free to perfusion-sensitive measurements of the apparent diffusion coefficient.
Adriano Massimiliano Priola, Sandro Massimo Priola, Dario Gned, Edoardo Piacibello, Diego Sardo, Guido Parvis

J Magn Reson Imaging· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, Anna Di Russo, Michele Magni, Guido Parvis

Int J Radiat Oncol Biol Phys· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of diffusion-weighted magnetic resonance imaging for assessing early treatment response in lymphoma patients.
Adriano Massimiliano Priola, Dario Gned, Guido Parvis, Davide Torti, Sandro Massimo Priola

Acta Radiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
Umberto Vitolo, Marco Ladetto, Carola Boccomini, Luca Baldini, Federico De Angelis, Guido Parvis

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.
Andrea Riccardo Filippi, Angela Botticella, Marilena Bellò, Barbara Botto, Anna Castiglione, Guido Parvis

Leuk Lymphoma· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
Corrado Tarella, Roberto Passera, Michele Magni, Fabio Benedetti, Andrea Rossi, Guido Parvis

J Clin Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT findings in primary pulmonary lymphomas.
Luciano Cardinale, Marco Allasia, Aldo Cataldi, Fabrizio Ferraris, Guido Parvis

Radiol Med· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
Davide Rossi, Clara Deambrogi, Daniela Capello, Michaela Cerri, Monia Lunghi, Guido Parvis

Br J Haematol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Umberto Vitolo, Anna Marina Liberati, Maria Giuseppina Cabras, Massimo Federico, Emanuele Angelucci, Guido Parvis

Haematologica· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Alessandro M Gianni, Michele Magni, Maurizio Martelli, Massimo Di Nicola, Carmelo Carlo-Stella, Guido Parvis

Blood· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis